Status
Conditions
Treatments
About
This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials. Pridopidine will be given at a dose of 45 mg twice daily p.o. (or via feeding tube).
Each patient will be followed for 2 years with regularly scheduled visits. The screening and baseline visits will be performed in person; subsequent visits may occur in person or remotely. Recommended in-person visits will occur at Weeks 12, 52, 78, and end of treatment (Week 104 or early termination). If the patient is unable to complete the visits in person, these visits may also be completed remotely.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Use of prohibited medications within the 4 weeks prior to baseline.
Loading...
Central trial contact
Victoria Wang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal